Related Experiment Video

Updated: Jun 5, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Pathobiology of stent thrombosis after drug-eluting stent implantation

Marc Vorpahl1, Saami K Yazdani, Masataka Nakano

  • 1CV Path Institute Inc. 19 Firstfield Road. Gaithersburg, MD, USA.

Current Pharmaceutical Design
|January 7, 2011
PubMed

Insights

First-generation drug-eluting stents (DES) improve coronary artery disease treatment but can cause late stent thrombosis (LST). Poor endothelialization and specific anatomical factors predict LST risk, necessitating further understanding of DES pathology.

Area of Science:

  • Cardiovascular pathology
  • Interventional cardiology
  • Biomaterials science

Background:

  • First-generation drug-eluting stents (DES) reduced restenosis after percutaneous coronary revascularization.
  • Late stent thrombosis (LST) emerged as a significant safety concern with DES implantation.
  • Understanding DES pathology in humans is crucial due to widespread use.

Purpose of the Study:

  • To investigate the pathological mechanisms underlying late stent thrombosis (LST) in patients with drug-eluting stents (DES).
  • To identify predictors of delayed arterial healing and LST in human autopsy studies.
  • To compare atherosclerotic changes between DES and bare-metal stents (BMS).

Main Methods:

  • Analysis of autopsy data from the CVPath DES registry.
  • Correlation of stent strut endothelialization with late stent thrombosis.
  • Identification of anatomical and pathological factors associated with LST.

Main Results:

  • Delayed arterial healing and poor endothelialization of stent struts are key predictors of LST.
  • Arterial healing is heterogeneous, influenced by plaque morphology and stent location.
  • Factors linked to LST include hypersensitivity, plaque rupture, bifurcations, malapposition, and stent fracture.
  • DES showed accelerated atherosclerotic changes compared to BMS.

Conclusions:

  • Poor endothelialization is the primary predictor of late stent thrombosis after DES implantation.
  • Heterogeneity in arterial healing and specific anatomical/pathological factors contribute to LST risk.
  • DES implantation is associated with accelerated atherosclerosis compared to bare-metal stents.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...